- Home
- LOT vs ZYME Comparison
LOT vs ZYME Comparison
Compare LOT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- ZYME
- Stock Information
- Founded
- LOT 1948
- ZYME 2003
- Country
- LOT China
- ZYME United States
- Employees
- LOT N/A
- ZYME N/A
- Industry
- LOT
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- LOT
- ZYME Health Care
- Exchange
- LOT NYSE
- ZYME Nasdaq
- Market Cap
- LOT 956.3M
- ZYME 867.6M
- IPO Year
- LOT N/A
- ZYME 2017
- Fundamental
- Price
- LOT $2.19
- ZYME $12.48
- Analyst Decision
- LOT
- ZYME Buy
- Analyst Count
- LOT 0
- ZYME 7
- Target Price
- LOT N/A
- ZYME $19.50
- AVG Volume (30 Days)
- LOT 84.9K
- ZYME 413.4K
- Earning Date
- LOT 06-25-2025
- ZYME 07-31-2025
- Dividend Yield
- LOT N/A
- ZYME N/A
- EPS Growth
- LOT N/A
- ZYME N/A
- EPS
- LOT N/A
- ZYME N/A
- Revenue
- LOT $924,349,000.00
- ZYME $93,384,000.00
- Revenue This Year
- LOT $40.53
- ZYME $44.71
- Revenue Next Year
- LOT $87.99
- ZYME $34.57
- P/E Ratio
- LOT N/A
- ZYME N/A
- Revenue Growth
- LOT 36.13
- ZYME 85.05
- 52 Week Low
- LOT $1.06
- ZYME $8.21
- 52 Week High
- LOT $7.42
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- LOT 56.35
- ZYME 53.22
- Support Level
- LOT $2.16
- ZYME $12.33
- Resistance Level
- LOT $2.26
- ZYME $13.44
- Average True Range (ATR)
- LOT 0.11
- ZYME 0.57
- MACD
- LOT -0.01
- ZYME 0.02
- Stochastic Oscillator
- LOT 60.71
- ZYME 54.85
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.